Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011))
Publikation: Spezielle Publikationen/Beiträge › Korrekturen (Errata und Widerrufe) › Begutachtung
Beitragende
Abstract
In Fig. 2c and f of our publication Schneeweiss et al. [1] we mistakenly placed wrong Kaplan Meier Plots. In the attached figure this was corrected. All other estimates concerning the survival including the regression models are correct. We apologize for the mistake. 1. Schneeweiss A, Ettl J, Luftner D et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88–95.Fig. 2. Progression-free survival (PFS) and overall survival (OS) for the total group analyzed. CDK4/6i, CDK4/6 inhibitors; ET, endocrine therapy; OS, overall survival; PFS, progression-free survival.
Details
| Originalsprache | Englisch |
|---|---|
| Seiten | 138-139 |
| Seitenumfang | 2 |
| Band | 55 |
| Fachzeitschrift | Breast |
| Publikationsstatus | Veröffentlicht - Feb. 2021 |
| Peer-Review-Status | Ja |
Externe IDs
| PubMed | 33413981 |
|---|